Patents by Inventor Nagisa NAKATA

Nagisa NAKATA has filed for patents to protect the following inventions. This listing includes patent applications that are pending as well as patents that have already been granted by the United States Patent and Trademark Office (USPTO).

  • Inactivated whole-virus influenza vaccine and method for preparing same
    Patent number: 11890338
    Abstract: An inactivated whole-virus influenza vaccine may have its antibody-inducing ability is maintained or enhanced and may cause fewer side reactions. A method for preparing an inactivated whole-virus influenza vaccine may use an embryonated chicken egg method, including subjecting a virus solution including a whole influenza virus collected from embryonated chicken eggs to a hypotonic treatment.
    Type: Grant
    Filed: September 26, 2019
    Date of Patent: February 6, 2024
    Assignees: DENKA COMPANY LIMITED, NATIONAL UNIVERSITY CORPORATION KUMAMOTO UNIVERSITY
    Inventors: Ryotaro Mitsumata, Shogo Misumi, Naoki Kishimoto, Takuma Gotanda, Nagisa Nakata
  • Mucosal adjuvant
    Patent number: 11707521
    Abstract: A mucosal adjuvant may have high mucosal immunogenicity and high safety and be useful in the preparation of mucosal vaccines, and a mucosal vaccine composition may include the same. Such mucosal adjuvant may include TGDK. A method for preparing the mucosal vaccine composition may include mixing TGDK with an immunogen.
    Type: Grant
    Filed: September 26, 2019
    Date of Patent: July 25, 2023
    Assignees: DENKA COMPANY LIMITED, NATIONAL UNIVERSITY CORPORATION KUMAMOTO UNIVERSITY
    Inventors: Shogo Misumi, Naoki Kishimoto, Ryotaro Mitsumata, Nagisa Nakata, Takuma Gotanda
  • SEASONAL INFLUENZA VACCINE CAPABLE OF INDUCING VIRUS-SPECIFIC ANTIBODY INTO NASAL CAVITY
    Publication number: 20220331419
    Abstract: Provided is a seasonal influenza vaccine having a higher efficacy than a split vaccine. A seasonal influenza vaccine which induces virus-specific antibodies in the nasal mucosa, comprises inactivated whole influenza virus particles as an active ingredient, and is to be administered intradermally at dose per administration of 15 ?g HA or more per strain as antigen.
    Type: Application
    Filed: September 2, 2020
    Publication date: October 20, 2022
    Applicant: DENKA COMPANY LIMITED
    Inventors: Ryotaro MITSUMATA, Asumi KANDA, Nagisa NAKATA, Shigetaka MIMORI
  • INACTIVATED WHOLE-VIRUS INFLUENZA VACCINE AND METHOD FOR PREPARING SAME
    Publication number: 20220031833
    Abstract: An inactivated whole-virus influenza vaccine may have its antibody-inducing ability is maintained or enhanced and may cause fewer side reactions. A method for preparing an inactivated whole-virus influenza vaccine may use an embryonated chicken egg method, including subjecting a virus solution including a whole influenza virus collected from embryonated chicken eggs to a hypotonic treatment.
    Type: Application
    Filed: September 26, 2019
    Publication date: February 3, 2022
    Applicants: DENKA COMPANY LIMITED, NATIONAL UNIVERSITY CORPORATION KUMAMOTO UNIVERSITY
    Inventors: Ryotaro MITSUMATA, Shogo MISUMI, Naoki KISHIMOTO, Takuma GOTANDA, Nagisa NAKATA
  • MUCOSAL ADJUVANT
    Publication number: 20220031838
    Abstract: A mucosal adjuvant may have high mucosal immunogenicity and high safety and be useful in the preparation of mucosal vaccines, and a mucosal vaccine composition may include the same. Such mucosal adjuvant may include TGDK. A method for preparing the mucosal vaccine composition may include mixing TGDK with an immunogen.
    Type: Application
    Filed: September 26, 2019
    Publication date: February 3, 2022
    Applicants: DENKA COMPANY LIMITED, NATIONAL UNIVERSITY CORPORATION KUMAMOTO UNIVERSITY
    Inventors: Shogo MISUMI, Naoki KISHIMOTO, Ryotaro MITSUMATA, Nagisa NAKATA, Takuma GOTANDA